logo-loader
RNS
Bioventix

BioVentix PLC - Director/PDMR Shareholding

RNS Number : 2629B
BioVentix PLC
29 January 2024
 

Bioventix plc

 

("Bioventix" or "the Company")

 

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 29 January 2024 Peter Harrison, Chief Executive Officer of the Company, sold 62,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 4,200 pence per Ordinary Share (the "Sale").

 

The Sale was facilitated to enable a new institutional investor to join the share register. Peter Harrison has undertaken not to dispose of any further Ordinary Shares for 12 months.

 

Following the Sale, Peter Harrison has a beneficial interest in 297,088 Ordinary Shares, representing approximately 5.7 per cent. of the issued share capital of the Company.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information please contact:

 

Bioventix plc

Peter Harrison

Bruce Hiscock

 

Chief Executive Officer

Chief Financial Officer

Tel: 01252 728 001

 

 

 

Cavendish Capital Markets Limited

Geoff Nash / Simon Hicks

Nigel Birks / Harriet Ward

 

Corporate Finance

Corporate Broking

Tel: 020 7220 0500

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Peter Harrison

2.

Reason for the Notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Bioventix plc

b)

LEI

213800225MHX7LZQY108

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 5 pence each

Identification code

GB00B4QVDF07

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

62,000 Ordinary Shares

4,200 pence

d)

Aggregated information:

 

·     Aggregated volume

 

·     Price

Sale of 62,000 Ordinary Shares at 4,200 pence each

e)

Date of the transaction

29 January 2024

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEASFNAEALEFA
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read